Recombinant tissue plasminogen activator

Recombinant tissue plasminogen activator (rtPA) is a protein involved in the breakdown of blood clots. It is a serine protease (EC 3.4.21.68) found on endothelial cells, the cells that line the blood vessels. As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.

History[edit | edit source]

The rtPA protein was first identified in 1982. It was approved by the Food and Drug Administration (FDA) in 1987 for use in acute myocardial infarction (heart attack) and in 1996 for acute ischemic stroke.

Medical uses[edit | edit source]

rtPA is used in some cases of diseases that feature blood clots, such as an acute ischemic stroke. However, use is contraindicated in cases of active internal bleeding, or a history of recent surgery.

Mechanism of action[edit | edit source]

rtPA is a serine protease that is produced by endothelial cells. This enzyme is released into the blood where it binds to fibrin clots and converts plasminogen to plasmin. Plasmin then degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.

Side effects[edit | edit source]

The most common side effect of rtPA is bleeding. Other side effects can include allergic reactions, cardiac arrhythmias, and a decrease in blood pressure.

See also[edit | edit source]

Recombinant tissue plasminogen activator Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.